MARKET

CTSO

CTSO

Cytosorbents
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.67
-0.06
-0.62%
After Hours: 9.66 -0.01 -0.05% 16:42 05/28 EDT
OPEN
9.67
PREV CLOSE
9.73
HIGH
10.01
LOW
9.57
VOLUME
329.64K
TURNOVER
--
52 WEEK HIGH
11.24
52 WEEK LOW
3.490
MARKET CAP
350.17M
P/E (TTM)
-17.7015
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CTSO stock price target is 14.58 with a high estimate of 17.00 and a low estimate of 11.50.

EPS

CTSO News

More
CytoSorbents Announces Virtual Annual Meeting
PR Newswire · 1d ago
CTSO: Q1 2020: CTSO Nabs FDA breakthrough designation and European approval for ticagrelor removal, Q1 Product revenue sets new record, Moving PT to $15/share
Zacks Small Cap Research · 05/19 13:03
The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12)
Benzinga · 05/13 11:40
CytoSorb OK'd in Europe to remove rivaroxaban during cardiothoracic surgery
CytoSorbents (NASDAQ:CTSO) announces that CytoSorb is now approved and immediately available in the European Union for the removal of rivaroxaban (Xarelto-
seekingalpha · 05/12 16:24
Stocks That Hit 52-Week Highs On Tuesday
Tuesday morning saw 85 companies set new 52-week highs.
Benzinga · 05/12 14:41
CytoSorb® is E.U. Approved to Remove Rivaroxaban, a Leading Factor Xa Inhibitor and Novel Oral Anticoagulant, During On-Pump Cardiothoracic Surgery
PR Newswire · 05/12 12:08
The Charts of Cytosorbents Suggest We Might See Further Gains Ahead
TheStreet.com · 05/08 19:24
Cramer Shares His Thoughts On DraftKings, Wells Fargo And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said that Omnicom Group Inc. (NYSE: OMC) is probably one of the last man standing in the advertising.
Benzinga · 05/08 11:52

Industry

Advanced Medical Equipment & Technology
+1.91%
Healthcare Equipment & Supplies
+1.61%

Hot Stocks

Symbol
Price
%Change

About CTSO

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company's purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company's CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery, autoimmune disease flares, cancer, cytokine release syndrome in cancer immunotherapy and cancer cachexia.
More

Webull offers kinds of Cytosorbents Corp stock information, including NASDAQ:CTSO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTSO stock news, and many more online research tools to help you make informed decisions.